Consano Bio’s C-1101 Receives FDA Fast Track Desig...
Category : ODD/BTA/FTA Status 19 August 2026FDA Designation Supports Development of Potential Treatment for Chronic Lumbosacral Radiculopathy...
Odd Bta Fta Status
Biogen’s Salanersen Receives FDA Breakthrough Ther...
Category : ODD/BTA/FTA Status 8 June 2026A Major Step Forward for SMA Treatment Biogen has announced that the U.S. Food and Drug Administr...
Thryv Therapeutics Advances THRV-1268 in Long QT S...
Category : ODD/BTA/FTA Status 27 April 2026Fast Track status + Phase 2/3 dosing marks a critical inflection point. A small biotech just made a...
Eris Lifesciences Disrupts the GLP-1 Market with ₹...
Category : ODD/BTA/FTA Status 23 March 2026The semaglutide price war in India just hit a new low. Eris Lifesciences Limited has launched its ge...
US FDA grants Breakthrough Therapy designation to...
Category : ODD/BTA/FTA Status 20 March 2026Sanofi announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy des...
Latest Newsletter Post
-
Newron Provides Update on Phase 3 E..
26 September 2026
-
Gossamer Bio submits NDA to US FDA..
26 September 2026
-
Roche’s Sefaxersen Meets Phase III..
24 September 2026
-
Amgen’s Dazodalibep Meets Phase 3 O..
24 September 2026
-
Ulefnersen Meets Phase 3 Endpoint i..
23 September 2026
